Table 1.
Baseline Characteristics in Study Population by Incident CHD
| Characteristic | Incident CHD | ||
|---|---|---|---|
| No | Yes | All | |
| No. of participants | 85 601 | 3821 | 89 422 |
| Sociodemographic factors | |||
| Baseline age, y | 55.0 (8.0) | 59.2 (7.1) | 55.2 (8.0) |
| Male sex, % | 41.8 | 64.5 | 42.8 |
| White race, % | 95.0 | 95.5 | 95.0 |
| University education, % | 40.8 | 31.6 | 40.4 |
| Townsend Deprivation Index* | −1.4 (3.0) | −1.2 (3.2) | −1.4 (3.0) |
| Lifestyle factors, % | |||
| Current smoker | 10.1 | 16.6 | 10.5 |
| Current regular alcohol drinker | 70.7 | 68.3 | 70.6 |
| Anthropometry | |||
| Body mass index, kg/m2 | 26.9 (4.6) | 27.9 (4.6) | 27.0 (4.6) |
| Waist circumference, cm | 88.5 (12.9) | 93.9 (12.5) | 88.7 (12.9) |
| Waist/hip ratio | 0.86 (0.09) | 0.91 (0.08) | 0.86 (0.09) |
| Lipids and apolipoproteins measured by clinical chemistry | |||
| LDL cholesterol, mmol/L | 3.7 (0.8) | 3.9 (0.8) | 3.7 (0.8) |
| HDL cholesterol, mmol/L | 1.5 (0.4) | 1.3 (0.3) | 1.5 (0.4) |
| Total triglycerides, mmol/L | 1.7 (1.0) | 2.0 (1.1) | 1.7 (1.0) |
| Apolipoprotein A‐I, g/L | 1.5 (0.3) | 1.5 (0.3) | 1.5 (0.3) |
| Apolipoprotein B, g/L | 1.1 (0.2) | 1.1 (0.2) | 1.1 (0.2) |
| Blood pressure and diabetes | |||
| Systolic blood pressure, mm Hg | 136.3 (18.4) | 144.8 (19.0) | 136.7 (18.5) |
| Baseline diabetes, %† | 2.0 | 4.5 | 2.1 |
| Fasting time, h | 3.0 (2.0) | 3.0 (1.0) | 3.0 (2.0) |
Baseline characteristics of those with and those without incident CHD during follow‐up among 89 422 participants. Analyses exclude those with missing or outlying values for metabolites or key covariates and those with prior CHD or taking statins at baseline. Continuous variables are presented as mean (SD) (except for skew variable fasting time, presented as median [quartile range]), and categorical variables are presented as column percentages. CHD indicates coronary heart disease; HDL, high‐density lipoprotein; and LDL, low‐density lipoprotein.
Area‐level measure of material deprivation.
The low diabetes prevalence is attributable to the exclusion of individuals with baseline cardiovascular disease, which had large overlap with the individuals with diabetes at baseline. Before excluding baseline cardiovascular disease, the prevalence of diabetes in the study population is 6% (the prevalence is also 6% for the whole UK Biobank participants).